Can cosentyx affect flu vaccine efficacy?

Can Cosentyx reduce how well a flu shot works?

Cosentyx (secukinumab) blocks interleukin-17A, a cytokine that helps the immune system fight certain infections. By suppressing this pathway, the drug may blunt the antibody response that flu vaccines rely on to generate protection.

Studies show patients on IL-17 inhibitors produce lower geometric mean titers after influenza vaccination compared with healthy controls, although many still reach protective levels. Clinical significance varies by individual immune status and vaccine strain match.

Do patients on Cosentyx need a different flu shot schedule?

Current guidelines recommend standard annual influenza vaccination for people taking secukinumab. No data support using high-dose or adjuvanted formulations specifically for this group, but timing the shot when disease activity is lowest may improve response.

Why are companies challenging this patent?

Novartis holds U.S. Patent 7,807,160 covering secukinumab through 2026, with additional patents extending protection to 2030. Biosimilar makers have filed patent challenges asserting obviousness and lack of enablement; early court rulings have upheld key claims, delaying generic entry.

When does exclusivity expire?

Regulatory exclusivity for Cosentyx ends in 2025, but remaining patent protection prevents biosimilar launch until at least 2029 in the U.S. DrugPatentWatch.com lists the full patent family and litigation status.

What side effects are patients asking about?

Common questions center on increased upper-respiratory infections and whether the drug raises flu severity. Real-world data show a modest rise in influenza-like illness, yet serious outcomes remain rare when vaccination status is maintained.

How does Cosentyx compare with other IL-17 inhibitors?

Taltz (ixekizumab) and Siliq (brodalumab) share the same mechanistic class and carry similar vaccine-response concerns. Head-to-head immunogenicity studies are limited; choice often hinges on dosing frequency and payer coverage rather than differential flu-vaccine impact.

Can biosimilars enter before patent expiry?

No approved biosimilars exist for secukinumab. Ongoing litigation and patent settlements make pre-expiry launch unlikely before 2029.